Global Neuraminidase Inhibitors Drug Market Research Report 2023
Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme.
According to QYResearch’s new survey, global Neuraminidase Inhibitors Drug market is projected to reach US$ 1386.5 million in 2029, increasing from US$ 928 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neuraminidase Inhibitors Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neuraminidase Inhibitors Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Neuraminidase Inhibitors Drug market is projected to reach US$ 1386.5 million in 2029, increasing from US$ 928 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neuraminidase Inhibitors Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neuraminidase Inhibitors Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Roche
- GSK
- Gilead Sciences
- Daiichi Sankyo
- AstraZeneca
- Pfizer
- Teva
- Bristol-Myers Squibb
- Sun Pharmaceutical
- Oseltamivir
- Zanamivir
- Peramivir
- Laninamivir
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market by Application
1.3.1 Global Neuraminidase Inhibitors Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2018-2029)
2.2 Neuraminidase Inhibitors Drug Growth Trends by Region
2.2.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neuraminidase Inhibitors Drug Historic Market Size by Region (2018-2023)
2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029)
2.3 Neuraminidase Inhibitors Drug Market Dynamics
2.3.1 Neuraminidase Inhibitors Drug Industry Trends
2.3.2 Neuraminidase Inhibitors Drug Market Drivers
2.3.3 Neuraminidase Inhibitors Drug Market Challenges
2.3.4 Neuraminidase Inhibitors Drug Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue
3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2018-2023)
3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2023)
3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2022
3.5 Neuraminidase Inhibitors Drug Key Players Head office and Area Served
3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NEURAMINIDASE INHIBITORS DRUG BREAKDOWN DATA BY TYPE
4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2018-2023)
4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029)
5 NEURAMINIDASE INHIBITORS DRUG BREAKDOWN DATA BY APPLICATION
5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2018-2023)
5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neuraminidase Inhibitors Drug Market Size (2018-2029)
6.2 North America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
6.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Neuraminidase Inhibitors Drug Market Size (2018-2029)
7.2 Europe Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2018-2029)
8.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Neuraminidase Inhibitors Drug Market Size (2018-2029)
9.2 Latin America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
9.4 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2018-2029)
10.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.1.5 Roche Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.2.5 GSK Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.3.5 Gilead Sciences Recent Development
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Detail
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.4.5 Daiichi Sankyo Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Neuraminidase Inhibitors Drug Introduction
11.5.4 AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Neuraminidase Inhibitors Drug Introduction
11.6.4 Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Neuraminidase Inhibitors Drug Introduction
11.7.4 Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.7.5 Teva Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Introduction
11.8.4 Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Detail
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Introduction
11.9.4 Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.9.5 Sun Pharmaceutical Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market by Application
1.3.1 Global Neuraminidase Inhibitors Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2018-2029)
2.2 Neuraminidase Inhibitors Drug Growth Trends by Region
2.2.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neuraminidase Inhibitors Drug Historic Market Size by Region (2018-2023)
2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029)
2.3 Neuraminidase Inhibitors Drug Market Dynamics
2.3.1 Neuraminidase Inhibitors Drug Industry Trends
2.3.2 Neuraminidase Inhibitors Drug Market Drivers
2.3.3 Neuraminidase Inhibitors Drug Market Challenges
2.3.4 Neuraminidase Inhibitors Drug Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue
3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2018-2023)
3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2023)
3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2022
3.5 Neuraminidase Inhibitors Drug Key Players Head office and Area Served
3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NEURAMINIDASE INHIBITORS DRUG BREAKDOWN DATA BY TYPE
4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2018-2023)
4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029)
5 NEURAMINIDASE INHIBITORS DRUG BREAKDOWN DATA BY APPLICATION
5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2018-2023)
5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neuraminidase Inhibitors Drug Market Size (2018-2029)
6.2 North America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
6.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Neuraminidase Inhibitors Drug Market Size (2018-2029)
7.2 Europe Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2018-2029)
8.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Neuraminidase Inhibitors Drug Market Size (2018-2029)
9.2 Latin America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
9.4 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2018-2029)
10.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.1.5 Roche Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.2.5 GSK Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.3.5 Gilead Sciences Recent Development
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Detail
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.4.5 Daiichi Sankyo Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Neuraminidase Inhibitors Drug Introduction
11.5.4 AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Neuraminidase Inhibitors Drug Introduction
11.6.4 Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Neuraminidase Inhibitors Drug Introduction
11.7.4 Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.7.5 Teva Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Introduction
11.8.4 Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Detail
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Introduction
11.9.4 Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2023)
11.9.5 Sun Pharmaceutical Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Laninamivir
Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Neuraminidase Inhibitors Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Neuraminidase Inhibitors Drug Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Neuraminidase Inhibitors Drug Market Share by Region (2018-2023)
Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Neuraminidase Inhibitors Drug Market Share by Region (2024-2029)
Table 12. Neuraminidase Inhibitors Drug Market Trends
Table 13. Neuraminidase Inhibitors Drug Market Drivers
Table 14. Neuraminidase Inhibitors Drug Market Challenges
Table 15. Neuraminidase Inhibitors Drug Market Restraints
Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Neuraminidase Inhibitors Drug Market Share by Players (2018-2023)
Table 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Table 19. Ranking of Global Top Neuraminidase Inhibitors Drug Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neuraminidase Inhibitors Drug Product Solution and Service
Table 23. Date of Enter into Neuraminidase Inhibitors Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2023)
Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2024-2029)
Table 29. Global Neuraminidase Inhibitors Drug Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2023)
Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2024-2029)
Table 33. North America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 48. Roche Company Detail
Table 49. Roche Business Overview
Table 50. Roche Neuraminidase Inhibitors Drug Product
Table 51. Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 52. Roche Recent Development
Table 53. GSK Company Detail
Table 54. GSK Business Overview
Table 55. GSK Neuraminidase Inhibitors Drug Product
Table 56. GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 57. GSK Recent Development
Table 58. Gilead Sciences Company Detail
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Neuraminidase Inhibitors Drug Product
Table 61. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 62. Gilead Sciences Recent Development
Table 63. Daiichi Sankyo Company Detail
Table 64. Daiichi Sankyo Business Overview
Table 65. Daiichi Sankyo Neuraminidase Inhibitors Drug Product
Table 66. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 67. Daiichi Sankyo Recent Development
Table 68. AstraZeneca Company Detail
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Neuraminidase Inhibitors Drug Product
Table 71. AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Pfizer Company Detail
Table 74. Pfizer Business Overview
Table 75. Pfizer Neuraminidase Inhibitors Drug Product
Table 76. Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Teva Company Detail
Table 79. Teva Business Overview
Table 80. Teva Neuraminidase Inhibitors Drug Product
Table 81. Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 82. Teva Recent Development
Table 83. Bristol-Myers Squibb Company Detail
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product
Table 86. Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Sun Pharmaceutical Company Detail
Table 89. Sun Pharmaceutical Business Overview
Table 90. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product
Table 91. Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 92. Sun Pharmaceutical Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Laninamivir
Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Neuraminidase Inhibitors Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Neuraminidase Inhibitors Drug Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Neuraminidase Inhibitors Drug Market Share by Region (2018-2023)
Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Neuraminidase Inhibitors Drug Market Share by Region (2024-2029)
Table 12. Neuraminidase Inhibitors Drug Market Trends
Table 13. Neuraminidase Inhibitors Drug Market Drivers
Table 14. Neuraminidase Inhibitors Drug Market Challenges
Table 15. Neuraminidase Inhibitors Drug Market Restraints
Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Neuraminidase Inhibitors Drug Market Share by Players (2018-2023)
Table 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Table 19. Ranking of Global Top Neuraminidase Inhibitors Drug Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neuraminidase Inhibitors Drug Product Solution and Service
Table 23. Date of Enter into Neuraminidase Inhibitors Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2023)
Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2024-2029)
Table 29. Global Neuraminidase Inhibitors Drug Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2023)
Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2024-2029)
Table 33. North America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 48. Roche Company Detail
Table 49. Roche Business Overview
Table 50. Roche Neuraminidase Inhibitors Drug Product
Table 51. Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 52. Roche Recent Development
Table 53. GSK Company Detail
Table 54. GSK Business Overview
Table 55. GSK Neuraminidase Inhibitors Drug Product
Table 56. GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 57. GSK Recent Development
Table 58. Gilead Sciences Company Detail
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Neuraminidase Inhibitors Drug Product
Table 61. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 62. Gilead Sciences Recent Development
Table 63. Daiichi Sankyo Company Detail
Table 64. Daiichi Sankyo Business Overview
Table 65. Daiichi Sankyo Neuraminidase Inhibitors Drug Product
Table 66. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 67. Daiichi Sankyo Recent Development
Table 68. AstraZeneca Company Detail
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Neuraminidase Inhibitors Drug Product
Table 71. AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Pfizer Company Detail
Table 74. Pfizer Business Overview
Table 75. Pfizer Neuraminidase Inhibitors Drug Product
Table 76. Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Teva Company Detail
Table 79. Teva Business Overview
Table 80. Teva Neuraminidase Inhibitors Drug Product
Table 81. Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 82. Teva Recent Development
Table 83. Bristol-Myers Squibb Company Detail
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product
Table 86. Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Sun Pharmaceutical Company Detail
Table 89. Sun Pharmaceutical Business Overview
Table 90. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product
Table 91. Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2023) & (US$ Million)
Table 92. Sun Pharmaceutical Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Neuraminidase Inhibitors Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Neuraminidase Inhibitors Drug Market Share by Type: 2022 VS 2029
Figure 3. Oseltamivir Features
Figure 4. Zanamivir Features
Figure 5. Peramivir Features
Figure 6. Laninamivir Features
Figure 7. Global Neuraminidase Inhibitors Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Neuraminidase Inhibitors Drug Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Online Pharmacy Case Studies
Figure 12. Others Case Studies
Figure 13. Neuraminidase Inhibitors Drug Report Years Considered
Figure 14. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Neuraminidase Inhibitors Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Region: 2022 VS 2029
Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Players in 2022
Figure 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2022
Figure 20. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 22. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 26. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2018-2029)
Figure 34. China Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 42. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 46. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 49. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 50. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 51. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 52. AstraZeneca Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 53. Pfizer Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 54. Teva Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 56. Sun Pharmaceutical Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Figure 1. Global Neuraminidase Inhibitors Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Neuraminidase Inhibitors Drug Market Share by Type: 2022 VS 2029
Figure 3. Oseltamivir Features
Figure 4. Zanamivir Features
Figure 5. Peramivir Features
Figure 6. Laninamivir Features
Figure 7. Global Neuraminidase Inhibitors Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Neuraminidase Inhibitors Drug Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Online Pharmacy Case Studies
Figure 12. Others Case Studies
Figure 13. Neuraminidase Inhibitors Drug Report Years Considered
Figure 14. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Neuraminidase Inhibitors Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Region: 2022 VS 2029
Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Players in 2022
Figure 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2022
Figure 20. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 22. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 26. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2018-2029)
Figure 34. China Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 42. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 46. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 49. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 50. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 51. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 52. AstraZeneca Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 53. Pfizer Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 54. Teva Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 56. Sun Pharmaceutical Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
